HQY vs NVST
HealthEquity vs Envista Holdings — AI-powered side-by-side comparison
VS
NVST
Envista Holdings
68
Buy
| Metric | HQY | NVST |
|---|
| AI Score |
64
|
68
|
| Price |
$106.83
|
$28.20
|
| P/E Ratio |
38.75×
|
47.71×
|
| ROE |
10.2%
|
1.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.7%
|
55.5%
|
| Debt / Equity |
0.48×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.8
|
58.7
|
| Beta |
0.21
|
0.861
|
| Expected Upside |
+1.0%
|
+1.7%
|
AI Committee View
Current Innellis committee reasoning for HQY versus NVST.
NVST leads by 4 points.
NVST scores 68/100 (Buy) versus HQY at 64/100 (Buy).
HQY Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 4 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 15.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly RSI at 76 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 15.3% signals elevated volatility — Risk
NVST Committee View
80% agreement
5 analysts
The primary driver is eps growing 83.6% yoy. The main limiting factor is p/e of 47.7 is expensive by classic value standards. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- EPS growing 83.6% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 47.7 is expensive by classic value standards — Value
- ROE of only 3.1% -- cheap may mean cheap for a reason — Value